UA98125C2 - Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний - Google Patents

Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний

Info

Publication number
UA98125C2
UA98125C2 UAA200905266A UAA200905266A UA98125C2 UA 98125 C2 UA98125 C2 UA 98125C2 UA A200905266 A UAA200905266 A UA A200905266A UA A200905266 A UAA200905266 A UA A200905266A UA 98125 C2 UA98125 C2 UA 98125C2
Authority
UA
Ukraine
Prior art keywords
dihydropyrazolon
cardiovascular
substituted
treatment
diseases
Prior art date
Application number
UAA200905266A
Other languages
English (en)
Ukrainian (uk)
Inventor
Каи Теде
Инго ФЛАММЕ
Феликс ОМЕ
Енс-Керим Эргюден
Фридерике ШТОЛЛЬ
Йоахим Шумахер
Ханно ВИЛЬД
Петер Колькхоф
Хартмут Бекк
Йорг Кельдених
Метин АКБАБА
Марио Еске
Original Assignee
Баер Шеринг Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баер Шеринг Фарма Акциенгезельшафт filed Critical Баер Шеринг Фарма Акциенгезельшафт
Publication of UA98125C2 publication Critical patent/UA98125C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Данная заявка касается новых замещенных производных дигидропиразолонаспособа их получения, а также их применения для получения лекарственных средств для лечения и/или профилактики заболеваний, в частности сердечнососудистых и гематологических заболеваний, заболеваний почек, а также способствованию заживлению ран.
UAA200905266A 2006-10-26 2007-10-12 Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний UA98125C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006050516A DE102006050516A1 (de) 2006-10-26 2006-10-26 Substituierte Dihydropyrazolone und ihre Verwendung
PCT/EP2007/008877 WO2008067871A1 (de) 2006-10-26 2007-10-12 Substituierte dihydropyrazolone zur behandlung kardiovaskulärer und hämatologischer erkrankungen

Publications (1)

Publication Number Publication Date
UA98125C2 true UA98125C2 (ru) 2012-04-25

Family

ID=38734870

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200905266A UA98125C2 (ru) 2006-10-26 2007-10-12 Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний

Country Status (41)

Country Link
US (5) US8389520B2 (ru)
EP (3) EP2383269B1 (ru)
JP (2) JP5247712B2 (ru)
KR (1) KR101455879B1 (ru)
CN (2) CN101631785B (ru)
AR (1) AR063392A1 (ru)
AU (1) AU2007328052B2 (ru)
BR (1) BRPI0717367B8 (ru)
CA (1) CA2667382C (ru)
CO (1) CO6170359A2 (ru)
CR (2) CR10750A (ru)
CU (2) CU23743B7 (ru)
CY (1) CY1114272T1 (ru)
DE (1) DE102006050516A1 (ru)
DK (2) DK2546253T3 (ru)
ES (3) ES2621787T3 (ru)
GT (1) GT200900095A (ru)
HK (2) HK1140478A1 (ru)
HN (1) HN2009000784A (ru)
HR (2) HRP20130779T1 (ru)
IL (2) IL198289A (ru)
MA (1) MA30914B1 (ru)
MX (1) MX2009004324A (ru)
MY (1) MY169564A (ru)
NO (1) NO343308B1 (ru)
NZ (2) NZ596583A (ru)
PE (3) PE20120635A1 (ru)
PH (1) PH12013500578B1 (ru)
PL (2) PL2546253T3 (ru)
PT (2) PT2546253E (ru)
RS (1) RS52924B (ru)
RU (2) RU2469031C2 (ru)
SG (1) SG176421A1 (ru)
SI (1) SI2084151T1 (ru)
SV (1) SV2009003236A (ru)
TN (1) TN2009000132A1 (ru)
TW (3) TW201630605A (ru)
UA (1) UA98125C2 (ru)
UY (1) UY30663A1 (ru)
WO (1) WO2008067871A1 (ru)
ZA (1) ZA200902705B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
WO2009134754A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
FR2940651B1 (fr) * 2008-12-29 2013-05-03 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
SG172422A1 (en) 2008-12-29 2011-07-28 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
MX2011007054A (es) * 2008-12-29 2011-11-29 Sanofi Sa Derivados de 2-il-pirazol-3(2h)-ona, su preparacion y su aplicacion en terapeutica como activadores de hif.
FR2949466A1 (fr) * 2009-08-28 2011-03-04 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
US9273034B2 (en) 2011-10-25 2016-03-01 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
EP2628722A1 (en) * 2012-02-16 2013-08-21 Bayer CropScience AG CF3O-containing enaminoketones and their utilization for the preparation of CF3O-containing pyrazoles
KR20140138208A (ko) * 2012-03-30 2014-12-03 다이이찌 산쿄 가부시키가이샤 4-알카노일아미노-3-피라졸론 유도체
WO2013167552A1 (de) * 2012-05-08 2013-11-14 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von triazol-verbindungen
IN2014MN02314A (ru) 2012-05-29 2015-08-07 Momentive Performance Mat Inc
EA031647B1 (ru) 2013-03-29 2019-02-28 Такеда Фармасьютикал Компани Лимитед 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
UA119855C2 (uk) 2013-10-17 2019-08-27 Байєр Фарма Акцієнгезелльшафт Фармацевтичні лікарські форми, які містять 1-[6-(морфолін-4-іл)піримідин-4-іл]-4-(1h-1,2,3-триазол-1-іл)-1h-піразол-5-олат натрію
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CN107778262A (zh) * 2016-08-24 2018-03-09 尹玉新 1,5‑双取代四氮唑类化合物及其制备方法和应用
CN109694380B (zh) * 2017-10-23 2022-09-27 中国医药研究开发中心有限公司 二氢吡唑啉酮类化合物及其制备方法和医药用途
CN111825690B (zh) * 2019-04-17 2022-09-27 中国医药研究开发中心有限公司 一种phd抑制剂的新晶型及其制备方法
US11579118B2 (en) 2019-06-03 2023-02-14 Tdw Delaware, Inc. Single point contact triaxial sensor head for an inline inspection tool
US10702525B1 (en) 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents
US20230135152A1 (en) * 2020-02-11 2023-05-04 AcuraStem Incorporated Pikfyve kinase inhibitors
CN115551839A (zh) 2020-02-18 2022-12-30 拜耳公司 作为农药的杂芳基-三唑化合物
TW202140444A (zh) * 2020-03-20 2021-11-01 美商阿克比治療有限公司 Ｐｈｄ抑制劑化合物、組成物及使用方法
EP3888684A1 (en) 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance
EP4138825A1 (en) 2020-04-20 2023-03-01 Akebia Therapeutics Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE424016C (de) 1923-05-20 1926-01-14 Allg Vergasungs Ges M B H Fa Schachtofen mit Schwelaufsatz zur Vergasung und Verschwelung bituminoeser Stoffe
FR1519069A (fr) 1966-04-13 1968-03-29 Geigy Ag J R Dérivés du sulfanilamide et leur préparation
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
DE4204919A1 (de) 1992-02-19 1993-08-26 Bayer Ag Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen
DE4240168A1 (de) 1992-11-30 1994-06-01 Bayer Ag Cumarin-Derivate, Verfahren zu ihrer Herstellung und ihrer Verwendung
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH10306077A (ja) * 1997-05-07 1998-11-17 Daiichi Rajio Isotope Kenkyusho:Kk ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
PL358393A1 (en) * 2000-03-20 2004-08-09 N-Gene Research Laboratories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
JP4316893B2 (ja) 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
DE60223720T2 (de) 2001-12-18 2008-10-30 Merck & Co., Inc. Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7652033B2 (en) 2003-03-27 2010-01-26 Emory University HIF-1 inhibitors
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
JP2007527854A (ja) 2003-05-01 2007-10-04 パナシア ファーマシューティカルズ インコーポレーテッド 虚血関連状態の治療方法
CA2530679A1 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
AT7634U1 (de) 2004-06-29 2005-06-27 Binder Co Ag Detektiervorrichtung und sortiervorrichtung
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
RU2401258C2 (ru) 2005-03-16 2010-10-10 Авентис Фармасьютикалз Инк. Дипиразолы в качестве средств для центральной нервной системы
MX2007013263A (es) * 2005-04-26 2008-01-22 Neurosearch As Novedosos derivados oxadiazol y su uso medico.
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
CU20090066A7 (es) 2011-09-21
EP2084151B1 (de) 2013-05-29
HRP20150396T1 (hr) 2015-05-08
GT200900095A (es) 2011-10-12
JP5300813B2 (ja) 2013-09-25
CY1114272T1 (el) 2016-08-31
JP2010507602A (ja) 2010-03-11
US8987261B2 (en) 2015-03-24
CN101631785B (zh) 2013-08-21
BRPI0717367B8 (pt) 2021-05-25
PE20120620A1 (es) 2012-05-27
KR101455879B1 (ko) 2014-11-03
EP2383269B1 (de) 2017-01-18
DE102006050516A1 (de) 2008-04-30
US20120121727A1 (en) 2012-05-17
BRPI0717367A2 (pt) 2013-10-22
EP2383269A2 (de) 2011-11-02
UY30663A1 (es) 2008-05-31
US9168249B2 (en) 2015-10-27
EP2546253A1 (de) 2013-01-16
IL198289A0 (en) 2010-02-17
CU20110119A7 (es) 2012-01-31
NZ596583A (en) 2013-05-31
HN2009000784A (es) 2012-02-27
CR10750A (es) 2009-09-16
JP2011006486A (ja) 2011-01-13
US8653111B2 (en) 2014-02-18
CN103342696B (zh) 2015-03-11
US20150148381A1 (en) 2015-05-28
HK1140478A1 (en) 2010-10-15
HK1190153A1 (en) 2014-06-27
ZA200902705B (en) 2010-06-30
RU2469031C2 (ru) 2012-12-10
TW200833330A (en) 2008-08-16
TN2009000132A1 (en) 2010-10-18
AR063392A1 (es) 2009-01-28
TWI561237B (en) 2016-12-11
KR20090074811A (ko) 2009-07-07
CN101631785A (zh) 2010-01-20
AU2007328052A1 (en) 2008-06-12
AU2007328052B2 (en) 2013-11-07
EP2546253B1 (de) 2015-01-14
US20140031329A1 (en) 2014-01-30
TW201630605A (zh) 2016-09-01
RU2012134284A (ru) 2014-02-20
RS52924B (en) 2014-02-28
PE20080895A1 (es) 2008-09-05
CU24056B1 (es) 2014-12-26
MX2009004324A (es) 2009-05-12
EP2084151A1 (de) 2009-08-05
PH12013500578A1 (en) 2014-09-08
NZ576458A (en) 2011-12-22
PH12013500578B1 (en) 2014-09-08
TWI437991B (zh) 2014-05-21
ES2621787T3 (es) 2017-07-05
PL2084151T3 (pl) 2013-10-31
HRP20130779T1 (hr) 2013-09-30
PE20120635A1 (es) 2012-05-20
EP2383269A3 (de) 2012-01-11
CA2667382A1 (en) 2008-06-12
US20160229858A1 (en) 2016-08-11
WO2008067871A1 (de) 2008-06-12
TW201345526A (zh) 2013-11-16
CN103342696A (zh) 2013-10-09
NO20091655L (no) 2009-06-26
ES2534872T3 (es) 2015-04-29
SG176421A1 (en) 2011-12-29
JP5247712B2 (ja) 2013-07-24
IL221928A (en) 2015-10-29
DK2084151T3 (da) 2013-09-02
SI2084151T1 (sl) 2013-10-30
US8389520B2 (en) 2013-03-05
US20100305085A1 (en) 2010-12-02
NO343308B1 (no) 2019-01-28
PL2546253T3 (pl) 2015-08-31
CA2667382C (en) 2014-12-23
CR20140392A (es) 2014-09-16
BRPI0717367B1 (pt) 2020-09-08
DK2546253T3 (en) 2015-04-20
RU2611012C2 (ru) 2017-02-17
ES2421454T3 (es) 2013-09-02
MA30914B1 (fr) 2009-11-02
RU2009119431A (ru) 2010-12-10
MY169564A (en) 2019-04-22
CU23743B7 (es) 2012-01-31
SV2009003236A (es) 2010-01-19
PT2084151E (pt) 2013-07-18
PT2546253E (pt) 2015-05-07
CO6170359A2 (es) 2010-06-18
IL198289A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
UA98125C2 (ru) Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний
HK1122803A1 (ru)
UA105487C2 (ru) Замещенные дигидропиразолоны как ингибиторы hif-пролил-4-гидроксилазы
MX2010004074A (es) Combinacion 059.
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
NZ601350A (en) Method of treating arthritis
ITPD20050206A1 (it) Biomateriali in forma di fibra da impiegarsi come dispositivi medici nel trattamento delle ferite e loro processi di produzione
TN2009000503A1 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
WO2009030224A3 (de) Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
MX2011012505A (es) Piperidinas sustituidas.
UA112422C2 (uk) Заміщений натрій-1h-піразол-5-олат
TNSN08279A1 (en) Bayer healthcare ag
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
WO2008046407A3 (de) Verwendung von deuteriumdioxid zur behandlung von hyperproliferativen erkrankungen der haut
ATE500253T1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihre verwendung zur behandlung kardiovaskulärer erkrankungen
MX2011009277A (es) Composicion de leucocito activada.
MX2011012507A (es) Piperidinas sustituidas.
ATE455789T1 (de) Substituierte nonadepsipeptide
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
MX2009013709A (es) (oxazolidinon-5-ilmetil)-2-tiofenocarboxamidas sustituidas y su uso en el campo de la coagulación sanguínea.
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure